Skip to Main Content
Menu Button
About Us
The ModeX Mission
Leadership
Our Journey
OPKO Health
Science
Our Approach
Our MSTAR Platform
Our Nanoparticle Vaccine Platform
Publications, Posters, and Presentations
Pipeline
People
Careers
Life at ModeX
News & Events
A PHASE 1/2A, MULTICENTER, FIRST-IN-HUMAN, OPEN-LABEL CLINICAL TRIAL EVALUATING MDX2001, A TETRASPECIFIC T CELL ENGAGER-EXPANDER IN PATIENTS WITH ADVANCED SOLID TUMOR (NCT06239194)
2023 R&D Day
